This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
DMT is a powerful hallucinogenic drug found in several plants including the South American plant chacruna and when used recreationally is mixed with the ayahuasca plant to make the shamanic brew of the same name. The post Small Pharma stock market launch funds DMT-based depression drugtrial appeared first on.
TWO US clinical investigator sites have been opened for a phase 1 clinicaltrial for patients with soft tissue sarcoma and the first patient has been dosed.
China’s Kintor Pharmaceutical has begun late-stage US clinicaldevelopment of its potential COVID drug proxalutamide – but there is scepticism over the company’s claims about its research. The post Scepticism in press over Kintor’s COVID-19 US drugtrial appeared first on.
As the industry focuses on creating a more holistic, inclusive patient experience, here are key steps to consider in order to help bridge the gap between clinical research and the patient experience. The fact is, many minorities never learn about vital clinicaltrials in play, or that they’re eligible to participate.
Addressing any anxieties patients and caregivers have, including coming off existing medication, as well as questions regarding the trialdrug or the tests and procedures involved in the trial. Shifting towards decentralised trial designs can help solve some of the challenges around recruiting patients for orphan drugtrials.
(CDS), a leading technology provider focused on data collection and clinicaltrial management, today announced several updates in celebration of its tenth anniversary, including the company’s latest technological development, TrialKit AI, a machine-learning API. 888) 753-4777 carley.nolan@crucialdatasolutions.com.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content